The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.

Biotech VC Jonathan Silverstein has unveiled the next development in his quest to find a cure for Parkinson's with GBA.

The alliance gives Agilis a base in Japan and a partnership with a fellow CNS specialist to support its development of AAV vectors and gene therapies.

The split gives uniQure full rights to AMT-060 but leaves it without a partner to cofund R&D as it closes in on the start of a pivotal trial.

BeiGene is adding Medidata’s electronic patient-reported outcome solution to oncology clinical studies.

The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.

Sarepta offers Exondys 51 outside of the U.S. through a managed access program run by Clinigen, as an EMA decision is expected next year.

Erytech Pharma has formed a collaboration with Canada’s Queen’s University to advance its drug against the metabolic disorder arginase-1 deficiency.

Celgene has bought itself a spot toward the back of the pack in the PD-1 inhibitor market.